Latest News

Date Title Topic
11 Aug 2016 Developing a Framework of Collaboration Between the EMA and Academia Bioethics, legal and economic issues
09 Aug 2016 FDA Approves Pembrolizumab for Patients with Recurrent or Metastatic HNSCC with Disease Progression on or After Platinum-Containing Chemotherapy Head and neck cancers - Cancer Immunology and Immunotherapy
03 Aug 2016 NICE Issues Technology Appraisal Guidance for Nivolumab in Combination With Ipilimumab for Advanced Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
03 Aug 2016 New: Bone Sarcoma Guide for Patients
02 Aug 2016 EMA Recommends Extension of Therapeutic Indications for Ibrutinib Haematologic malignancies - Anticancer agents & Biologic therapy
01 Aug 2016 BRCA1 and BRCA2 in Ovarian Cancer
28 Jul 2016 EMA Recommends Granting a Marketing Authorisation for Pegylated Liposomal Formulation of Irinotecan for Metastatic Pancreatic Adenocarcinoma Gastrointestinal cancers - Anticancer agents & Biologic therapy
27 Jul 2016 Infection-Associated Cancers Epidemiology/Etiology/Cancer Prevention
26 Jul 2016 EMA Recommends Granting a Marketing Authorisation for Lenvatinib in the Treatment of Unresectable Advanced or Metastatic RCC Genitourinary cancers - Anticancer agents & Biologic therapy
26 Jul 2016 Press Release: ESMO Publishes Results of European Consortium Study on the Availability of Anti-neoplastic Medicines
25 Jul 2016 EMA Recommends Extension of Therapeutic Indications for Crizotinib Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
25 Jul 2016 July 2016 – Image of the Month
22 Jul 2016 EMA Recommends Granting a Marketing Authorisation for Cabozantinib in Advanced RCC Genitourinary cancers - Anticancer agents & Biologic therapy
21 Jul 2016 Press Release: ESMO 2018 Annual Congress to be Held in Munich
20 Jul 2016 PRAC Concludes Review of Idelalisib and Issues Updated Recommendations for Use Haematologic malignancies - Anticancer agents & Biologic therapy